Vertex Pharmaceuticals is a wide-moat biopharmaceutical company with a 36% net margin, compounder quality designation, strong 7.7 momentum score, and a 3-quarter earnings beat streak, trading at $450.46 with a suggested entry pullback target of $437.10 — offering a balanced risk-reward for accumulation on weakness despite concentration in cystic fibrosis medicines.
Thesis pillars
- Wide Moat Cf Franchise→Stable
- Momentum Continuation Above 200ma↓Deteriorating
- Earnings Beat Trajectory↑Improving
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 13, 2026
Vertex Pharmaceuticals Incorpor (VRTX) Stock Analysis
Breakout setup
Healthcare · Biotechnology
Sell if holding. Analyst target reached at $529.69 — A.R:R is negative (-0.3) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: CF medicines.
Vertex Pharmaceuticals commercializes medicines for cystic fibrosis (five approved CF modulators), sickle cell disease and beta thalassemia (CASGEVY, approved 2023), and acute pain (JOURNAVX, FDA-approved January 2025). Substantially all net product revenues derive from the CF... Read more
Sell if holding. Analyst target reached at $529.69 — A.R:R is negative (-0.3) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: CF medicines. Chart setup: Golden cross, above all MAs, RSI 60, MACD bullish. Score 5.7/10, moderate confidence.
Passes 4/7 gates (positive momentum, clean insider activity, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and earnings proximity 4d<=7d. Suitability: speculative.
About Vertex Pharmaceuticals Incorpor
About Vertex Pharmaceuticals Incorpor
Seven marketed medicines across three disease areas define Vertex Pharmaceuticals' commercial portfolio: five CF modulators including ALYFTREK and TRIKAFTA/KAFTRIO, CASGEVY for sickle cell disease and transfusion-dependent beta thalassemia (approved 2023), and JOURNAVX for acute pain (FDA-approved January 2025). The CF franchise reaches nearly three quarters of approximately 97,000 eligible CF patients in the U.S., Europe, Australia, and Canada, with reimbursement in more than 60 countries. From its March 2025 pharmacy launch through year-end, more than 550,000 JOURNAVX prescriptions were written and filled.
Vertex earns revenue primarily from the CF portfolio, where patients typically remain on modulators long-term after initiation. The company sells to a limited number of specialty pharmacy and specialty distributors in the U.S., which then resell to patients, health care providers, hospitals, and retail pharmacies. Outside the U.S., revenue flows through distributor arrangements and government-owned or government-supported hospital systems, with reimbursement negotiated country by country. CASGEVY carries a manufacturing cost significantly higher than small molecules as a percentage of revenue, given its complex ex-vivo CRISPR/Cas9 gene-editing process; roughly 300 patients with SCD or TDT initiated treatment globally in 2025. JOURNAVX competes in a market estimated at over 80 million annual acute pain prescriptions in the U.S., with more than 200 million covered lives as of January 2026. Five pivotal programs—povetacicept in IgA nephropathy (BLA rolling submission begun late 2025), inaxaplin in APOL1-mediated kidney disease, suzetrigine in diabetic peripheral neuropathy, zimislecel in type 1 diabetes, and povetacicept in primary membranous nephropathy—constitute the primary pipeline opportunities.
Show full overview
The CF franchise's pricing faces scrutiny from multiple regulatory bodies. The Colorado Prescription Drug Affordability Board selected TRIKAFTA for an affordability review in August 2023 and later found it ineligible for an upper payment limit—though the 10-K states that future reviews may not reach the same conclusion for TRIKAFTA or other Vertex therapies. At the federal level, the Centers for Medicare & Medicaid Services proposed the GUARD Model, a most-favored-nation pricing mechanism for government programs; the 10-K characterizes the related outcomes as subject to significant uncertainty. For CASGEVY, third-party payor acceptance and adequate reimbursement remain the primary commercial gating factors given the therapy's higher manufacturing cost relative to the CF portfolio.
See also: Healthcare · Biotechnology
From Vertex Pharmaceuticals Incorpor's most recent 10-K filing, extracted June 16, 2026.
Recent developments
updated 2026-10-29Recent Developments — Vertex Pharmaceuticals Incorpor
Latest news
- NEWS Analysts’ Top Healthcare Picks: Vertex Pharmaceuticals (VRTX), Unicycive Therapeutics (UNCY) - The Globe and Mail — The Globe and Mail positive
- NEWS Vertex Pharmaceuticals And 2 Other Top Biotech Stocks To Own - Simply Wall Street — Simply Wall Street positive
- NEWS Vertex Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch — MarketWatch negative
- NEWS Vertex Pharmaceuticals (VRTX) Expands Its Pipeline Reach, Is The Stock Fully Valued? - Yahoo Finance — Yahoo Finance positive
- NEWS Vertex Pharmaceuticals (VRTX) Expands Its Pipeline Reach, Is The Stock Fully Valued? - finance.yahoo.com — finance.yahoo.com positive
Generated 2026-10-29T11:08:52Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductCF medicines10-K Item 1A: 'Substantially all our net product revenues have been derived from the sale of our CF medicines.'
Material Events(8-K, last 90d)
- 2026-05-13Item 5.02LOWBoard approved 2026 Stock and Option Plan replacing the 2013 plan; approved by shareholders at the May 13, 2026 annual meeting. Routine compensatory arrangement update. No officer departure.SEC filing →
- 2026-04-29Item 5.02LOWDirector Suketu Upadhyay informed the board he will not stand for re-election at the 2026 annual meeting; departing to become CFO of Incyte Corporation. Board will reduce to 10 members. No disagreement with company cited.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $529.69 — A.R:R is negative (-0.3) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: CF medicines. Chart setup: Golden cross, above all MAs, RSI 60, MACD bullish. Prior stop was $498.43. Score 5.7/10, moderate confidence.
Analyst target $514.32 reached (−2.9% from $529.69); no take-profit level is published. Prior stop was $498.43. Stop-loss: $498.43.
Concentration risk — Product: CF medicines; Analyst target reached - limited upside remaining; Earnings in 4 days (event risk).
Vertex Pharmaceuticals Incorpor trades at a P/E of 30.8 (forward 26.0). TrendMatrix value score: 3.6/10. Verdict: Sell.
39 analysts cover VRTX with a consensus score of 4.1/5. Average price target: $571.
What does Vertex Pharmaceuticals Incorpor do?Vertex Pharmaceuticals commercializes medicines for cystic fibrosis (five approved CF modulators), sickle cell disease...
Vertex Pharmaceuticals commercializes medicines for cystic fibrosis (five approved CF modulators), sickle cell disease and beta thalassemia (CASGEVY, approved 2023), and acute pain (JOURNAVX, FDA-approved January 2025). Substantially all net product revenues derive from the CF franchise, sold through specialty pharmacy and specialty distributors in more than 60 countries. Pivotal programs in IgA nephropathy, APOL1-mediated kidney disease, diabetic neuropathy, and type 1 diabetes are in active development.